Evaluation of treatment of experimentally induced canine model of multiple sclerosis using laser activated non-expanded adipose derived stem cells

Abdallah, Ahmed N.; Shamaa, Ashraf A.; El‐Tookhy, Omar S.

doi:10.1016/j.rvsc.2019.05.016

Cited by 18 publications

(38 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown that MSCs can differentiate into monocytes and neurons in vitro and in vivo ( 24 ). MSCs can migrate to areas of injured tissue via expressions of receptors for chemokines such as CCR1, CXCR4, CXCR5, and CXCR6, and some growth factors ( 6 ).…”

Section: Mesenchymal Stem Cells (Mscs)mentioning

confidence: 99%

“…Therefore, this tissue is considered as a valuable source of the cell for cellular therapy. AD-MSCs have the neurogenic, cardiogenic, myogenic, chondrogenic, osteogenic, and adipogenic capacity in vitro , which can be obtained and used to stem cell therapy by less invasive methods ( 6 , 54 ). AD-MSCs can express α4 integrin, an adhesive molecule, and thereby have the ability to migrate in different organs ( 55 ).…”

Section: Human Adipose-derived Mscs (Ad-mscs)mentioning

confidence: 99%

“…However, the most of these therapeutic approaches are unable to stop the degeneration of nerve tissue in aggressive MS ( 5 ). Among these methods, stem cell based-cell therapies have a promising outlook for the remedy of neurological disorders by differentiation into astrocytes and oligodendrocytes effectively in vivo and in vitro as well as the secretions of neurotrophic agents which have immunoregulatory effects and regenerative roles for remyelination and thereby can decrease neural damages ( 6 ). There are some challenges for using stem cells as a curative approach in clinical trials because they can quickly proliferate and subsequently have a capacity for tumorigenicity ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic Aspects of Mesenchymal Stem Cell-Based Cell Therapy with a Focus on Human Amniotic Epithelial Cells in Multiple Sclerosis: A Mechanistic Review

ArefNezhad

Motedayyen

Mohammadi

2021

IJSC

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an inflammatory disease of central nervous system (CNS). The mmune system plays an important role in its pathogenesis. Current treatments are unable to cure patients and prevent the progression of MS lesions. Stem cell-based cell therapy has opened a new window for MS treatment. Stem cells regulate immune responses and improve axonal remyelination. Stem cells can be obtained from different origins such as embryonic, neural, bone marrow, and adipose tissues. But yet there is a challenge for the selection of the best cell source for stem cell therapy. Mesenchymal stem cells (MSCs) are a type of stem cell obtained from different origins and have significant immunomodulatory effects on the immune system. The increasing evidence have suggested that umbilical cord and adipose tissue can be a suitable source for isolation of MSCs. Moreover, human amniotic epithelial cells (hAECs) as novel stem cell origins by having immunoregulatory effects, regenerative effects, and less capacity of antigenicity can be a candidate for MS treatment. This review discussed the mechanistic effects of MSCs with a focus on human amniotic epithelial cells, which can be used to treatment and improvement of outcome in MS disease.

show abstract

Section: Mesenchymal Stem Cells (Mscs)mentioning

confidence: 99%

Section: Human Adipose-derived Mscs (Ad-mscs)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Aspects of Mesenchymal Stem Cell-Based Cell Therapy with a Focus on Human Amniotic Epithelial Cells in Multiple Sclerosis: A Mechanistic Review

ArefNezhad

Motedayyen

Mohammadi

2021

IJSC

View full text Add to dashboard Cite

show abstract

“…There is evidence supporting a role the antiinflammatory capacity of ADSCs for this devastating disorder [99][100][101], as well as their neuron-rebuilding capability. Indeed, both SVF and ADSCs appear to be effective in animal models of this disease [99,[102][103][104][105][106][107][108][109][110][111]. Bowles, et al, reported an advantage of SVF over ADSCs in the experimental autoimmune encephalomyelitis (EAE) model in the mouse [103,104].…”

Section: Msmentioning

confidence: 99%

Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3-year phase 1 study of 113 injections in 31 patients

Duma¹,

Kopyov²,

Kopyov³

et al. 2019

Mol Biol Rep

View full text Add to dashboard Cite

We have chosen to test the safety of human intracerebroventricular (ICV) brain injections of autologous non-geneticallymodified adipose-derived stromal vascular fraction (ADSVF). In this IRB-approved trial, 24 patients received ICV ADSVF via an implanted reservoir between 5/22/14 and 5/22/17. Seven others were injected via their ventriculo-peritoneal shunts. Ten patients had Alzheimer's disease (AD), 6 had amyotrophic lateral sclerosis (ALS), 6 had progressive multiple sclerosis (MS-P), 6 had Parkinson's "Plus" (PD+), 1 had spinal cord injury, 1 had traumatic brain injury, and 1 had stroke. Median age was 74 (range 41-83). Injections were planned every 2-3 months. Thirty-one patients had 113 injections. Patients received SVF injection volumes of 3.5-20 cc (median:4 cc) containing 4.05 × 10 5 to 6.2 × 10 7 cells/cc, which contained an average of 8% hematopoietic and 7.5% adipose stem cells. Follow-up ranged from 0 to 36 months (median: 9.2 months). MRIs post injection(s) were unchanged, except for one AD patient whose hippocampal volume increased from < 5th percentile to 48th percentile (NeuroQuant ® volumetric MRI). Of the 10 AD patients, 8 were stable or improved in tests of cognition. Two showed improvement in P-tau and ß-amyloid levels. Of the 6 MS-P patients all are stable or improved. Four of 6 ALS patients died of disease progression. Twelve of 111 injections (11%) led to 1-4 days of transient meningismus, and mild temperature elevation, which resolved with acetaminophen and/or dexamethasone. Two (1.8% of injections) required hospitalization for these symptoms. One patient (0.9% of injections) had his reservoir removed and later replaced for presumed infection. In this Phase 1 safety trial, ADSVF was safely injected into the human brain ventricular system in patients with no other treatment options. Secondary endpoints of clinical improvement or stability were particularly promising in the AD and MS-P groups. These results will be submitted for a Phase 2 FDA-approved trial.

show abstract

“…Dogs are a good preclinical animal model to study several degenerative and traumatic diseases in humans [16,17]. Recently, adipose SVF has been used for the treatment of several inflammatory and immune-mediated conditions in canines, such as osteoarthritis, tendinopathy, hip dysplasia and multiple sclerosis [10,11,18,19]. Despite the wide use of canine SVF cells in veterinary clinics, only two studies investigated the cellular component of freshly isolated canine SVF cells.…”

Section: Introductionmentioning

confidence: 99%

Tissue Harvesting Site Effect on the Canine Adipose Stromal Vascular Fraction Quantity and Quality

Hendawy

Uemura

et al. 2021

Animals

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) constitute a great promise for regenerative therapy, but these cells are difficultly recovered in large amounts. A potent alternative is the stromal vascular fraction (SVF), non-cultured MSCs, separated from adipose tissue (AT). We aim to evaluate AT harvesting site effect on the SVF cells’ quantity and quality in dogs. Subcutaneous abdominal fat, falciform ligament and peri-ovarian fat were sampled. After SVF isolation, the trypan blue exclusion test and a hemocytometer were used to assess the cell viability and cellular yield. SVF cells were labeled for four surface antigenic markers, clusters of differentiation CD90, CD44, CD29, and CD45, and then examined by flow cytometry. Semi-quantitative RT-PCR was used to evaluate the gene expression of the former markers in addition to OCT-4 and CD34. SVF cells in the peri-ovarian AT recorded the highest viability% (99.63 ± 0.2%), as well as a significantly higher cellular yield (36.87 ± 19.6 × 106 viable cells/gm fat, p < 0.001) and a higher expression of adipose-derived mesenchymal stem cells AD-MSCs surface markers than that of other sites. SVF cells from the peri-ovarian site revealed a higher expression of MSC markers (CD90, CD44, and CD29) and OCT-4 compared to the other sites, with weak CD45 and CD34 expressions. The positive OCT-4 expression demonstrated the pluripotency of SVF cells isolated from different sites. To conclude, the harvesting site is a strong determinant of SVF cells’ quantity and quality, and the peri-ovarian site could be the best AT sampling site in dogs.

show abstract

Evaluation of treatment of experimentally induced canine model of multiple sclerosis using laser activated non-expanded adipose derived stem cells

Cited by 18 publications

References 38 publications

Therapeutic Aspects of Mesenchymal Stem Cell-Based Cell Therapy with a Focus on Human Amniotic Epithelial Cells in Multiple Sclerosis: A Mechanistic Review

Therapeutic Aspects of Mesenchymal Stem Cell-Based Cell Therapy with a Focus on Human Amniotic Epithelial Cells in Multiple Sclerosis: A Mechanistic Review

Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3-year phase 1 study of 113 injections in 31 patients

Tissue Harvesting Site Effect on the Canine Adipose Stromal Vascular Fraction Quantity and Quality

Contact Info

Product

Resources

About